Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. In 2003 he moved to Brisbane, and works as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying immunity and identification of novel biomarkers in lymphoma, with continuous NHMRC funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Diamantina Institute, and was appointed Diamantina Cancer Program Head in 2016. In 2018 to current, he moved to Mater Research, where he is Executive Director, as well Director of MRI-UQ.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. We utilise a broad range of approaches including genomics, molecular and cellular biology techniques and functional immunoassays. Several of our studies are linked with the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

211 works between 1993 and 2024

21 - 40 of 211 works

2023

Conference Publication

Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse

Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191

Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse

2023

Conference Publication

Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL

Verner, E., Johnston, A., Pati, N., Hawkes, E., Lee, H. P., Cochrane, T., Cheah, C. Y., Filshie, R., Purtill, D., Sia, H., Enjeti, A. K., Brown, C., Murphy, N., Curnow, J., Lee, K., Gandhi, M. K., Butcher, B. E. and Trotman, J. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_313

Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL

2023

Conference Publication

Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma

Tobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189

Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma

2023

Journal Article

Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia

Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631

Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia

2023

Journal Article

A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma

George, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078

A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma

2023

Journal Article

Genetic susceptibility to EBV-related disease

Gandhi, Maher K. (2023). Genetic susceptibility to EBV-related disease. Blood, 141 (13), 1499-1500. doi: 10.1182/blood.2022019180

Genetic susceptibility to EBV-related disease

2023

Journal Article

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Agrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

2023

Journal Article

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Trotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher K., Cochrane, Tara, Badoux, Xavier, Carlson, Julia, Nkhoma, Gloria, Butcher, Belinda, Nikpour, Armin, Fulham, Michael and Johnston, Anna M. (2023). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. HemaSphere, 7 (3), e836. doi: 10.1097/HS9.0000000000000836

Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

2023

Journal Article

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

Casey, Mika, Segawa, Kane, Law, Soi Cheng, Sabdia, Muhamamed Bilal, Nowlan, Bianca, Salik, Basit, Lee, Carol, Winterford, Clay, Pearson, Sally, Madore, Jason, Dougall, William C., Gandhi, Maher K. and Nakamura, Kyohei (2023). Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia, 37 (2), 379-387. doi: 10.1038/s41375-022-01794-9

Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma

2023

Conference Publication

ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS

Rijal, Sewa, Lim, Jun Hee, Smyth, Lillian, Coombes, Caitlin, Jain, Sanjiv, Saxena, Kartik, Trotman, Judith, Verner, Emma, Gandhi, Maher K., Gandhi, Kaushal and Talaulikar, Dipti (2023). ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS. HOBOKEN: WILEY.

ANALYSIS OF THE GENETIC LANDSCAPE IN ELDERLY DIFFUSE LARGE B CELL LYMPHOMA AGED ≥ 75 YEARS IDENTIFIES NEW TARGETABLE MUTATIONS

2022

Conference Publication

Identification of Genetic Subtypes in Follicular Lymphoma

Shelton, Victoria, Isaev, Keren, Liu, Ting, Silva, Anjali, Detroja, Rajesh, Bakhtiari, Mehran, Calvente, Lourdes, Hong, Michael, Modi, Saloni, Hershenfeld, Samantha A., Ludvigsen, Maja, d'Amore, Francesco Annibale, Brodtkorb, Marianne, Johnson, Nathalie A., Baetz, Tara, LeBrun, David, Tobin, Josh, Gandhi, Maher K., Mungall, Andrew J., Steidl, Christian, Delabie, Jan, Tremblay-Lemay, Rosemarie, Kahl, Brad S., Evens, Andrew M and Kridel, Robert (2022). Identification of Genetic Subtypes in Follicular Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-164610

Identification of Genetic Subtypes in Follicular Lymphoma

2022

Journal Article

Crebbp mutations are associated with shorter time to progression in limited-stage follicular lymphoma treated with radiation

Hershenfeld, Samantha A., Shelton, Victoria, Bakhtiari, Mehran, Calvente, Lourdes, Lajkosz, Katherine, Isaev, Keren, Silva, Anjali, Liu, Ting, Brodtkorb, Marianne, d'Amore, Francesco Annibale, Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, Gandhi, Maher, Tobin, Joshua W.D., Baetz, Tara, LeBrun, David, Johnson, Nathalie A., Mungall, Andrew J., Crump, Michael, Delabie, Jan, Gospodarowicz, Mary, Hodgson, David, Hong, Michael, Kukreti, Vishal, Kuruvilla, John, Prica, Anca, Tremblay-Lemay, Rosemarie, Tsang, Richard and Kridel, Robert (2022). Crebbp mutations are associated with shorter time to progression in limited-stage follicular lymphoma treated with radiation. Blood, 140 (S1), 3532-3533. doi: 10.1182/blood-2022-156571

Crebbp mutations are associated with shorter time to progression in limited-stage follicular lymphoma treated with radiation

2022

Journal Article

The PO4-tential for less toxic CAR T-cell therapies

Tobin, Joshua W.D., Green, Michael R. and Gandhi, Maher K. (2022). The PO4-tential for less toxic CAR T-cell therapies. Cancer Immunology Research, 10 (12), 1422-1422. doi: 10.1158/2326-6066.cir-22-0793

The PO4-tential for less toxic CAR T-cell therapies

2022

Journal Article

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Lymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0

Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

2022

Conference Publication

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17

Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

2022

Journal Article

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

Gandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

2022

Journal Article

Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders

Sabdia, Muhammed B., Patch, Ann-Marie, Tsang, Hennes and Gandhi, Maher K. (2022). Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Blood Reviews, 56 100969, 100969. doi: 10.1016/j.blre.2022.100969

Neoantigens: the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders

2022

Journal Article

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

Ma, Man Chun John, Tadros, Saber, Bouska, Alyssa, Heavican, Tayla, Yang, Haopeng, Deng, Qing, Moore, Dalia, Akhter, Ariz, Hartert, Keenan, Jain, Neeraj, Showell, Jordan, Ghosh, Sreejoyee, Street, Lesley, Davidson, Marta, Carey, Christopher, Tobin, Joshua, Perumal, Deepak, Vose, Julie M., Lunning, Matthew A., Sohani, Aliyah R., Chen, Benjamin J., Buckley, Shannon, Nastoupil, Loretta J., Davis, R. Eric, Westin, Jason R., Fowler, Nathan H., Parekh, Samir, Gandhi, Maher, Neelapu, Sattva ... Green, Michael R. (2022). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 107 (3), 690-701. doi: 10.3324/haematol.2020.274258

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

2021

Journal Article

Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas

Bednarska, Karolina, Nath, Karthik, Nicol, William and Gandhi, Maher K. (2021). Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 50 100832, 100832. doi: 10.1016/j.blre.2021.100832

Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas

2021

Journal Article

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

Shanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

Funding

Past funding

  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au